Citi Maintains a 'Buy' on The Medicines Company (MDCO); Wins Patent Extension Ruling
Tweet Send to a Friend
Citi maintains a 'Buy' on The Medicines Company (Nasdaq: MDCO), raises PT from $12 to $21.
Citi analyst says, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Citi analyst says, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


